BIOGEN

MMM · Medicare/Medicaid

Discussions regarding drug cost and pricing policy and issues related to the Medicaid 340B program, no specific bill.

PHA · Pharmacy

Issues relating to drug cost and pricing policy, no current bill. Pharmacy Benefit Manager legislation related to patient access to therapies. Education and discussions regarding pharmaceutical issues related to supply chain, no specific bill.

TAX · Taxation/Internal Revenue Code

Issues related to tax reform and tax policy, implementation of Tax Cuts and Jobs Act of 2017 (P.L.115-97), policies related to OECD on the taxation of global income.

TRD · Trade (domestic/foreign)

Trade-related public policy around tariffs and intellectual property, no related bills

HCR · Health Issues

Discussions regarding drug pricing and supply chain issues; rare diseases; Alzheimer's policy, screening and diagnosis, dementia care; ALS, Lupus and Kidney related policy issues. Issues related to patient affordability and access issues, including copay cards, copay accumulators, copay maximizers, coverage issues, no specific bill numbers. Engage on public policy associated with orphan drug act, rare disease research, screening, detection and patient access for rare therapies. Public Policy efforts around Alzheimer's screening and diagnosis Issues related to H.R.1492/S.832, EPIC Act, equalizes the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation laws. ORPHAN CURES Act, no current bill number Public policy around patients access and affordability for necessary and life-saving medications prescribed by their doctors. S.864, HELP Copays Act, to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-share

Literal federal measure citations: H.R.1492, S.832, S.864